BlackRock Institutional Trust’s Fate Therapeutics FATE Stock Holding History

BlackRock Institutional Trust’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14K	Hold	5,728	–	–	﹤0.01%	3781
2016 Q3	$18K	Hold	5,728	–	–	﹤0.01%	3819
2016 Q2	$10K	Sell	5,728 -63,666	-92%	-$115K	﹤0.01%	3851
2016 Q1	$125K	Buy	69,394 +27,578	+66%	+$56.8K	﹤0.01%	3686
2015 Q4	$141K	Buy	41,816 +36,088	+630%	+$152K	﹤0.01%	3704
2015 Q3	$31K	Buy	5,728 +3,986	+229%	+$27.2K	﹤0.01%	3858
2015 Q2	$11K	Buy	+1,742	New	+$10.4K	﹤0.01%	3871

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Institutional Trust's FATE Position: Q4 2016 in Review

BlackRock Institutional Trust held its Fate Therapeutics (FATE) position steady in Q4 2016 at 5,728 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3781.

BlackRock Institutional Trust first reported a position in FATE in Q2 2015 and has held it in 7 quarters since. The position peaked at $141K in Q4 2015. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

BlackRock Institutional Trust held 5,728 shares of Fate Therapeutics worth $14K as of Q4 2016.
BlackRock Institutional Trust left its Fate Therapeutics share count unchanged in Q4 2016.
Fate Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3781 holding.
BlackRock Institutional Trust first reported a position in Fate Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Institutional Trust's Fate Therapeutics position peaked at $141K in Q4 2015.
37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.